Samsung Bioepis Co Ltd said on Monday it will fund and develop multiple original drugs in partnership with Japan's Takeda Pharmaceutical Co Ltd, expanding its business scope beyond copies of existing biologic drugs. More »
A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed/File Photo South Korea’s Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Joh... More »
SEOUL Biosimilars maker Samsung Bioepis, part of South Korea’s top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc’s rheumatoid arthritis drug Humira. Samsung Bioepis sa... More »
SEOUL Samsung Bioepis Co Ltd, which aims to become a force in the fledgling biosimilar drugs industry, has filed a lawsuit against the originator of the world’s best-selling drug, to stop it blocking the launch of its own version. The unit of South Korea’s Sam... More »
